Results 141 to 150 of about 6,337 (198)

Effectiveness of azvudine versus nirmatrelvir/ritonavir for hospitalized patients with SARS-CoV-2 infection and pre-existing liver diseases. [PDF]

Virol J
Su G, Gao F, Yang M, Wang L, Liang L, Li S, Li G, Han N, Li G, Qian G, Zhang S, Luo H, Zhang D, Liang H, Ren Z.   +14 more
europepmc   +1 more source

Analysis of California Senate Bill 1473: COVID-19 Therapeutics [PDF]

, 2022
California Health Benefits Review Program
core  

Time to anti-cancer treatment resumption after SARS-CoV-2 infection in patients with active haematological diseases undergoing combined antiviral treatments. [PDF]

J Antimicrob Chemother
Matteini E, Pinnetti C, Frondizi F, Rando E, Chiuchiarelli M, Metafuni E, Mastrorosa I, Alma E, Mazzotta V, Santangelo R, Marchetti S, Sanguinetti M, Sica S, Torti C, Antinori A, Cingolani A.   +15 more
europepmc   +1 more source

SARS-CoV-2 Infection and Antiviral Strategies: Advances and Limitations. [PDF]

Viruses
Soares VC, Moreira IBG, Dias SSG.
europepmc   +1 more source

Real-world effectiveness and safety of oral Azvudine versus Paxlovid for COVID-19 in patients with kidney disease: a multicenter, retrospective, cohort study. [PDF]

BMC Infect Dis
Rao B, Wang D, Yang M, Zhao C, Cheng M, Li S, Zhang D, Luo H, Qian G, Wang L, Zhang S, Li G, Li G, Yu Z, Ren Z.   +14 more
europepmc   +1 more source

Risk Factors for Seeking Medical Care Following Nirmatrelvir-Ritonavir (Paxlovid) Treatment for COVID-19: "Symptom Rebound". [PDF]

Viruses
Bhargava A, Szpunar S, Sharma M, Saravolatz L.   +3 more
europepmc   +1 more source

Paxlovid-induced Tacrolimus Toxicity in a Renal Transplant Recipient [PDF]

Doughty, Reece
core  

The unprecedented Paxlovid journey from milligrams to millions of patient doses during the Covid-19 pandemic. [PDF]

Commun Med (Lond)
Yu W, Krishnan MK, Weekly M, Shanker RM, Doshi P, Ragan JA, Greene RA, Gampper B, Caron S, McKillop A, Ludwig J, Dolsten M.   +11 more
europepmc   +1 more source

Genetic Predictors of Paxlovid Treatment Response: The Role of IFNAR2, OAS1, OAS3, and ACE2 in COVID-19 Clinical Course. [PDF]

J Pers Med
Buchynskyi M, Kamyshna I, Halabitska I, Petakh P, Oksenych V, Kamyshnyi O.   +5 more
europepmc   +1 more source

Multi-omics and machine learning identify novel biomarkers and therapeutic targets of COVID-19. [PDF]

Front Immunol
Zhou Y, Fan P, Zhang H, Han S, Bai M, Wang J, Wang Q.   +6 more
europepmc   +1 more source